The 36-month beta value for PASG is at 1.46. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PASG is 51.33M, and currently, shorts hold a 3.31% of that float. The average trading volume for PASG on December 27, 2024 was 592.17K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PASG) stock’s latest price update
Passage Bio Inc (NASDAQ: PASG)’s stock price has decreased by -1.42 compared to its previous closing price of 0.66. However, the company has seen a -0.54% decrease in its stock price over the last five trading sessions. https://thefly.com reported 2024-11-29 that Wedbush assumed coverage of Passage Bio with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline of four programs and additional options to license IND-enabling research from UPenn supported Passage’s upsized IPO, but the current valuation looks to be a “deep discount” compared to the potential that PBFT02 for frontotemporal dementia can achieve, the analyst tells investors.
PASG’s Market Performance
PASG’s stock has fallen by -0.54% in the past week, with a monthly drop of -13.38% and a quarterly drop of -4.90%. The volatility ratio for the week is 8.26% while the volatility levels for the last 30 days are 15.73% for Passage Bio Inc The simple moving average for the last 20 days is -13.75% for PASG stock, with a simple moving average of -29.15% for the last 200 days.
Analysts’ Opinion of PASG
Many brokerage firms have already submitted their reports for PASG stocks, with Wedbush repeating the rating for PASG by listing it as a “Outperform.” The predicted price for PASG in the upcoming period, according to Wedbush is $4 based on the research report published on November 29, 2024 of the current year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PASG reach a price target of $7. The rating they have provided for PASG stocks is “Buy” according to the report published on September 03rd, 2024.
PASG Trading at -1.83% from the 50-Day Moving Average
After a stumble in the market that brought PASG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.66% of loss for the given period.
Volatility was left at 15.73%, however, over the last 30 days, the volatility rate increased by 8.26%, as shares sank -2.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.70% upper at present.
During the last 5 trading sessions, PASG fell by -0.89%, which changed the moving average for the period of 200-days by -48.96% in comparison to the 20-day moving average, which settled at $0.7541. In addition, Passage Bio Inc saw -35.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PASG starting from ORBIMED ADVISORS LLC, who sale 230,321 shares at the price of $0.60 back on Dec 20 ’24. After this action, ORBIMED ADVISORS LLC now owns 7,404,869 shares of Passage Bio Inc, valued at $138,193 using the latest closing price.
ORBIMED ADVISORS LLC, the 10% Owner of Passage Bio Inc, sale 54,181 shares at $0.84 during a trade that took place back on Dec 09 ’24, which means that ORBIMED ADVISORS LLC is holding 7,643,285 shares at $45,512 based on the most recent closing price.
Stock Fundamentals for PASG
Current profitability levels for the company are sitting at:
- -12.61 for the present operating margin
- 0.59 for the gross margin
The net margin for Passage Bio Inc stands at -11.64. The total capital return value is set at -0.79. Equity return is now at value -69.15, with -48.97 for asset returns.
Currently, EBITDA for the company is -98.34 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 5.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.15.
Conclusion
In conclusion, Passage Bio Inc (PASG) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
